^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-10 stimulant

    Related drugs:
    Apply
    Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma (NCT01745588)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    12/01/2012
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    CD34
    |
    dexamethasone • pomalidomide
    Pomalidomide Treatment in Patients With Kaposi Sarcoma (NCT04577755)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    04/22/2024
    Initiation :
    03/18/2022
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    CD4
    |
    pomalidomide
    First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer (BIG) (NCT06253611)
    Phase 2
    GERCOR - Multidisciplinary Oncology Cooperative...
    Not yet recruiting
    Last update posted :
    02/19/2024
    Initiation :
    03/01/2024
    Primary completion :
    03/01/2026
    Completion :
    03/01/2029
    PD-L1
    |
    Opdivo (nivolumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD) (NCT02185820)
    Phase 1/2
    European Myeloma Network
    Completed
    Last update posted :
    06/30/2023
    Initiation :
    06/01/2014
    Primary completion :
    07/01/2015
    Completion :
    01/01/2023
    CRP
    |
    carfilzomib • dexamethasone • pomalidomide
    Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas (NCT04305444)
    Phase 2
    Zhejiang DTRM Biopharma
    Recruiting
    Last update posted :
    05/02/2023
    Initiation :
    04/24/2020
    Primary completion :
    03/01/2024
    Completion :
    03/01/2024
    BCL2
    |
    pomalidomide • DTRM-555 • DTRMWXHS-12
    Pomalidomide for Kaposi Sarcoma in People With or Without HIV (NCT01495598)
    Phase 1/2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/01/2022
    Initiation :
    01/10/2012
    Primary completion :
    05/17/2022
    Completion :
    05/17/2022
    CD8 • CD4
    |
    pomalidomide
    Study of Pomalidomide in Anal Cancer Precursors (SPACE) (NCT03113942)
    Phase 2
    Kirby Institute
    Active, not recruiting
    Last update posted :
    03/31/2022
    Initiation :
    06/14/2017
    Primary completion :
    03/31/2019
    Completion :
    12/31/2022
    CD4
    |
    pomalidomide